Apyx Medical Corporation Stock News

Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla. , May 30, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of the proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, is once again taking center stage—this tim...

The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the ...

Apyx Medical Corporation (NASDAQ:APYX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Jeremy Feffer – LifeSci Advisors Charlie Goodwin – Chief Executive Officer Matt Hill – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Capital Group Sam Eiber – BTIG Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical First...

Beloved Personality of "The Real Housewives of New Jersey" Provides a Real Take on the Problem of Loose Skin and the Power of Body Contouring Technology CLEARWATER, Fla. , May 1, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® today ...

Two studies report favorable clinical outcomes and safety data for Renuvion ® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medi...

CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th.

Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla. , March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®,...

Apyx Medical Corporation (NASDAQ:APYX ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Operator Greetings. Welcome to the Apyx Medical Fourth Quarter and Full Year 2024 C...